Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Takara Bio is part of Takara Holdings and is a leading Japanese life science and CDMO (Contract Development and Manufacturing Organization) company specializing in gene and cell therapy, PCR diagnostics, and advanced biotech tools, with worldwide presence. Major brand names and subsidiaries (Clontech, Cellartis, Takara Bio USA) expand its global reach and R&D footprint, while its platform technologies include the RetroNectin gene transduction method and Cellartis iPSC system. The clinical pipeline is currently focused on engineered TCR-T programs (notably NY-ESO-1 siTCR), oncolytic viruses, and advanced diagnostics. Employees and revenue figures are current as of 2024.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Takara.